Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic

StephenW

Journal of Viral Hepatitis
<http://cirrus.mail-list.com/hepatitis-b/27823981.html>

Pretreatment HBeAg level and an early decrease in HBeAg level predict
virologic response to entecavir treatment for HBeAg-positive chronic
hepatitis B

J. H. Kwon1,

J. W. Jang1,

S. Lee2,

J. Lee2,

K. W. Chung1,

Y. S. Lee1,

J. Y. Choi1

Article first published online: 20 NOV 2011

DOI: 10.1111/j.1365-2893.2011.01509.x

© 2011 Blackwell Publishing Ltd

Summary. There are few reports on hepatitis B e antigen (HBeAg) titres
during nucleos(t)ide analogues treatment. We investigated the changes in
HBeAg levels in patients treated with entecavir and the usefulness of HBeAg
quantification for predicting antiviral response. Ninety-five consecutive
HBeAg-positive patients treated with entecavir for more than 48 weeks were
enrolled. Serum levels of hepatitis B surface antigen (HBsAg), HBeAg and
HBV DNA were assessed at 4-week intervals to week 24 and thereafter at
12-week intervals. Virologic response (Y1VR) was defined as an undetectable
HBV DNA level at week 48 of therapy. During 48 weeks, HBeAg and HBV DNA
level decreased significantly in a biphasic manner and HBsAg level tended
to decease. Fifty-three patients (55.8%) attained Y1VR. Pretreatment HBeAg
levels were significantly lower in the Y1VR group than in no Y1VR group. At
week 4 and 12 of therapy, 25% and 41.4% of patients showed a decrease of
HBeAg levels with >0.5 log10 and >1.0 log10 from baseline, respectively.
These patients achieved more Y1VR than those with less decrease of HBeAg
levels (97.7%vs 22.2% and 86.2%vs 29.3%, respectively). HBeAg level at week
12 had higher predictive values for Y1VR than HBV DNA level. Multivariate
analysis revealed that a pretreatment HBeAg level of <360 PEIU/mL and the
reduction in HBeAg level >1.0 log10 at week 12 were associated with Y1VR.
These results suggest that pretreatment HBeAg level and an early decrease
in HBeAg level are useful measurements for predicting one-year virologic
response during entecavir treatment.



(6.合.彩)足球.篮球...各类投注开户下注

第一投注现金网:招代理年薪10万以上:yyu.cc

StephenW

中国病毒性肝炎
<http://cirrus.mail-list.com/hepatitis-b/27823981.html&gt;

预处理HBeAg的水平，早在HBeAg水平下降预测
恩替卡韦治疗HBeAg阳性慢性病​​毒学应答
B型肝炎

J. H.权1，

J. W.长1，

S.李2，

J.李2，

K. W.涌1，

Y. S.李1，

J. Y.彩1

文章首先在网上公布：2011年11月20日

DOI：10.1111/j.1365-2893.2011.01509.x

© 2011布莱克韦尔出版有限公司

摘要。有少数乙型肝炎e抗原（HBeAg）滴度报告
在核苷（酸）IDE类似物治疗。我们调查的变化
用恩替卡韦治疗的患者HBeAg的水平和HBeAg的有用
定量预测抗病毒反应。九十五个连续
与恩替卡韦治疗超过48周的HBeAg阳性患者
入学。乙肝表面抗原（HBsAg），HBeAg和血清
HBV - DNA进行了评估每隔4周，24周，其后
12个星期的时间间隔。病毒学应答（Y1VR）被定义为一个检测不到
治疗48周时HBV DNA水平。在48周，HBeAg和HBV DNA
在双相方式和水平显著下降HBsAg水平趋向
到去世。五十三例（55.8％）达到Y1VR。预处理大三阳
水平Y1VR组显著低于没有Y1VR组。在
第4周和12治疗，25％和41.4％的患者呈减少
HBeAg的水平> 0.5> 1.0 LOG10和LOG10，分别从基线。
这些患者实现用较少的HBeAg减少以上这些Y1VR
的水平（97.7％比22.2％和86.2％比29.3％，分别）。周时的HBeAg的水平
12例为Y1VR HBV DNA水平高于预测值。多元
分析表明，预处理<360 PEIU / ml和HBeAg的水平
在12周时HBeAg的水平> 1.0 log10的减少与Y1VR关联。
这些结果表明，预处理HBeAg的水平和年初减少
在HBeAg水平是有用的测量预测一年的病毒​​学
恩替卡韦治疗期间的响应。